{"contentid": 488726, "importid": NaN, "name": "Keytruda challenger takes center stage at ASCO 2021", "introduction": "This year\u00e2\u0080\u0099s annual meeting of the American Society of Clinical Oncology (ASCO) is a chance for Shanghai\u00e2\u0080\u0099s Junshi Biosciences to shine.", "content": "<p>This year&rsquo;s annual meeting of the American Society of Clinical Oncology (ASCO) is a chance for Shanghai&rsquo;s Junshi Biosciences (HKEX: 1877) to shine.</p>\n<p>Together with Californian biosimilars company Coherus BioSciences (Nasdaq: CHRS), Junshi has been developing a novel checkpoint blocker, toripalimab, which could represent a challenge to established immuno-oncology options, notably Merck &amp; Co&rsquo;s (NYSE: MRK) Keytruda (pembrolizumab).</p>\n<p>Marketed as Tuoyi, the treatment became the first domestic anti-PD-1 monoclonal antibody approved for marketing in China, after a 2018 nod for the second-line treatment of unresectable or metastatic melanoma.</p>\n<p>In the USA, a rolling submission is underway in metastatic nasopharyngeal carcinoma (NPC), an indication for which the therapy has secured Breakthrough Therapy designation.</p>\n<p>Coherus has been working with Junshi since February 2021, under the terms of a development and commercialization deal for the USA and Canada, which could be worth as much as $1.1 billion.</p>\n<h2>ASCO data</h2>\n<p>In a sign of the significance of the results, results for toripalimab have been selected for discussion at a plenary session taking place on Sunday, June 6.</p>\n<p>The anti-PD-1 antibody is being trialled as a first-line option for recurrent or metastatic NPC, in the Phase III JUPITER-02 study.</p>\n<p>Chief medical officer Patricia Keegan said: &ldquo;Treatment of nasopharyngeal carcinoma, a specific type of head-and-neck cancer, is challenging, as the diagnosis usually occurs when the cancer is in an advanced stage and treatment options are limited.&rdquo;</p>\n<p>Junshi is serious about pushing the checkpoint blocker forward into high-impact treatment settings, with more than 30 company-sponsored clinical studies covering more than 15 indications underway globally.</p>\n<p>With a focus on China and the USA, pivotal trials are ongoing or completed targeting cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.</p>\n<p>Critically, the therapy was successfully included in China&rsquo;s updated National Reimbursement Drug List in 2020, a prerequisite for gaining broad levels of reimbursement in the country.</p>", "date": "2021-05-25 11:04:00", "meta_title": NaN, "meta_keywords": "ASCO, Junshi, treatment, clinical, Keytruda, takes, center, stage, challenger, shine, HKEX, Biosciences, chance, Oncology, Society, American, meeting, year", "meta_description": "This year\u00e2\u0080\u0099s annual meeting of the American Society of Clinical Oncology (ASCO) is a chance for Shanghai\u00e2\u0080\u0099s Junshi Biosciences (HKEX: 1877) to shine.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-25 10:29:30", "updated": "2021-05-25 11:04:33", "access": NaN, "url": "https://www.thepharmaletter.com/article/keytruda-challenger-takes-center-stage-at-asco-2021", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "junshi_big.jpg", "image2id": "junshi_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "ASCO, Conferences, Drug Trial, Research", "geography_tag": "China, USA", "company_tag": "Coherus BioSciences, Junshi Biosciences", "drug_tag": "toripalimab", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-25 11:04:00"}